240 related articles for article (PubMed ID: 32005243)
1. Genomic profiles and transcriptomic microenvironments in 2 patients with synchronous lung adenocarcinoma and lung squamous cell carcinoma: a case report.
Wu L; Kang P; Tao S; Zhao Z; Chen L; Xiao Y; Tan Q
BMC Med Genomics; 2020 Jan; 13(1):15. PubMed ID: 32005243
[TBL] [Abstract][Full Text] [Related]
2. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N
J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309
[TBL] [Abstract][Full Text] [Related]
3. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
Cheng W; Xu B; Zhang H; Fang S
Thorac Cancer; 2021 Sep; 12(18):2458-2467. PubMed ID: 34328274
[TBL] [Abstract][Full Text] [Related]
4. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Kim A; Lim SM; Kim JH; Seo JS
Front Immunol; 2021; 12():598671. PubMed ID: 33717076
[TBL] [Abstract][Full Text] [Related]
5. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
[TBL] [Abstract][Full Text] [Related]
6. Evidence for common clonal origin of multifocal lung cancers.
Wang X; Wang M; MacLennan GT; Abdul-Karim FW; Eble JN; Jones TD; Olobatuyi F; Eisenberg R; Cummings OW; Zhang S; Lopez-Beltran A; Montironi R; Zheng S; Lin H; Davidson DD; Cheng L
J Natl Cancer Inst; 2009 Apr; 101(8):560-70. PubMed ID: 19351924
[TBL] [Abstract][Full Text] [Related]
7. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H; Arai K; Mizuno H; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Maruyama T; Kuwabara K; Nishizawa T; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K
Cancer Sci; 2024 Jun; 115(6):1763-1777. PubMed ID: 38527308
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
10. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment.
Cai MC; Zhao X; Cao M; Ma P; Chen M; Wu J; Jia C; He C; Fu Y; Tan L; Xue X; Yu Z; Zhuang G
J Pathol; 2020 Jun; 251(2):147-159. PubMed ID: 32222046
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
Qu Y; Cheng B; Shao N; Jia Y; Song Q; Tan B; Wang J
Aging (Albany NY); 2020 Mar; 12(6):4757-4777. PubMed ID: 32209727
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
Isaeva OI; Sharonov GV; Serebrovskaya EO; Turchaninova MA; Zaretsky AR; Shugay M; Chudakov DM
J Immunother Cancer; 2019 Oct; 7(1):279. PubMed ID: 31665076
[TBL] [Abstract][Full Text] [Related]
14. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
[TBL] [Abstract][Full Text] [Related]
15. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
[TBL] [Abstract][Full Text] [Related]
16. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
17. Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report.
Nishimura R; Yoshida T; Torasawa M; Kashihara T; Ohe Y
Thorac Cancer; 2023 Jan; 14(2):206-209. PubMed ID: 36453575
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
[TBL] [Abstract][Full Text] [Related]
19. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
20. Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response.
Lucchetta M; da Piedade I; Mounir M; Vabistsevits M; Terkelsen T; Papaleo E
BMC Cancer; 2019 Aug; 19(1):824. PubMed ID: 31429720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
